NASDAQ: CAPRCapricor Therapeutics Inc Stock Ownership - Who owns Capricor Therapeutics?
Insider buying vs selling
Have Capricor Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Anthony Bergmann | CHIEF FINANCIAL OFFICER | 2025-03-03 | 2,500 | $1.39 | $3.47kBuy |
| Frank Litvack | Director | 2025-03-03 | 25,000 | $1.39 | $34.75kBuy |
| Frank Litvack | Director | 2025-03-03 | 2,543 | $13.67 | $34.76kSell |
| Linda Marban | CHIEF EXECUTIVE OFFICER | 2025-03-03 | 25,000 | $1.39 | $34.75kBuy |
| George W. Dunbar Jr. | Director | 2025-03-03 | 750 | $1.39 | $1.04kBuy |
| Earl M. Collier Jr. | Director | 2025-02-27 | 750 | $1.39 | $1.04kBuy |
| Karen Krasney | EVP GENERAL COUNSEL | 2024-12-13 | 8,000 | $1.39 | $11.12kBuy |
| Frank Litvack | Director | 2024-12-03 | 20,391 | $1.10 | $22.43kBuy |
CAPR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when CAPR insiders and whales buy or sell their stock.
CAPR Shareholders
What type of owners hold Capricor Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Nippon Shinyaku Co Ltd | 15.51% | 7,090,351 | $49.07M | Insider |
| Fountainhead Capital Partners Ltd | 12.14% | 5,551,000 | $38.41M | Insider |
| Sinai Medical Center Cedars | 8.86% | 4,049,959 | $28.03M | Insider |
| Eduardo Marban | 7.24% | 3,307,863 | $22.89M | Insider |
| John Edward A. St | 6.78% | 3,101,574 | $21.46M | Insider |
| Blackrock Inc | 6.53% | 2,984,063 | $20.65M | Institution |
| Louis J. Grasmick | 6.43% | 2,937,729 | $20.33M | Insider |
| Peter M. Kash | 6.39% | 2,920,446 | $20.21M | Insider |
| Wexford Capital LP | 5.70% | 2,606,778 | $18.04M | Insider |
| Vanguard Group Inc | 5.04% | 2,305,078 | $15.95M | Institution |
CAPR vs Biotech Stocks
Capricor Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.